Real-World Outcomes of Patients With Baseline Neuropathy and/or Diabetes Mellitus Receiving Enfortumab Vedotin-Based Regimens for Advanced Urothelial Carcinoma in the UNITE Database

Overview of attention for article published in Clinical Genitourinary Cancer, January 2026

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (91st percentile)
Above-average Attention Score compared to outputs of the same age and source (63rd percentile)

Mentioned by

news: 1 news outlet

twitter: 17 X users

Readers on

mendeley: 1 Mendeley

So far, Altmetric has seen 17 X posts from 17 X users, with an upper bound of 81,001 followers.

RT @AJangMD: Excited to share our work, as we now move EV+P to the MIBC space #GU26 Appreciate the mentorship from @JasonBrownMDPhD @koshki…

RT @DrRishabhOnco: Real-World Outcomes of Patients With Baseline Neuropathy and/or Diabetes Mellitus Receiving Enfortumab Vedotin-Based Reg…

Real-World Outcomes of Patients With Baseline Neuropathy and/or Diabetes Mellitus Receiving Enfortumab Vedotin-Based Regimens for Advanced Urothelial Carcinoma in the UNITE Database - Clinical Genitourinary Cancer https://t.co/vWNRLmuDft

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 13 additional X posts.